QQ客服 官方微博 反馈留言

	Switching to anastrozole plus goserelin vs continued tamoxifen for adjuvant therapy of premenopausal early-stage breast cancer: preliminary results from a randomized trial
	Li, Jian-wei; Liu, Guang-yu; Ji, Ya-jie; Yan, Xia; Pang, Da; Jiang, Ze-fei; Chen, De-dian; Zhang, Bin; Xu, Bing-he; Shao, Zhi-ming
	2019
卷号	11页码:299-307
关键词	breast cancer adjuvant therapy anastrozole tamoxifen GnRH analogs aromatase inhibitors
ISSN号	1179-1322
DOI	10.2147/CMAR.S183672
URL标识	查看原文
收录类别	SCIE
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/6345247
专题	中国医学科学院 北京协和医学院
推荐引用方式 GB/T 7714	Li, Jian-wei,Liu, Guang-yu,Ji, Ya-jie,et al. Switching to anastrozole plus goserelin vs continued tamoxifen for adjuvant therapy of premenopausal early-stage breast cancer: preliminary results from a randomized trial[J],2019,11:299-307.
APA	Li, Jian-wei.,Liu, Guang-yu.,Ji, Ya-jie.,Yan, Xia.,Pang, Da.,...&Shao, Zhi-ming.(2019).Switching to anastrozole plus goserelin vs continued tamoxifen for adjuvant therapy of premenopausal early-stage breast cancer: preliminary results from a randomized trial.,11,299-307.
MLA	Li, Jian-wei,et al."Switching to anastrozole plus goserelin vs continued tamoxifen for adjuvant therapy of premenopausal early-stage breast cancer: preliminary results from a randomized trial".11(2019):299-307.

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。